Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run [Yahoo! Finance]
NASCENT BIOTECH INC (NBIO)
NASDAQ:AMEX Investor Relations:
nascentbiotech.com/investor-relations
Company Research
Source: Yahoo! Finance
clinical-stage biotechnology Company developing monoclonal antibodies targeting various cancer types, announces that it is embarking on a fresh manufacturing run to ensure Pritumumab ("PTB") supplies are at maximum potency when patient dosing begins in the upcoming Phase II clinical trial. "Taking the time to navigate this opportunity with proper care and diligence is a step that demonstrates our commitment to the best interests of our investors, partners, shareholders, and potential future patients," remarked Sean Carrick, CEO of NBIO. "No one likes delays, but patience and care at this critical stage is necessary in maximizing patient outcomes and long-term shareholder value. We want to be careful not to make hasty decisions while exploring all options. This announcement comes as the Company prepares for a Phase II trial that follows a very successful Phase I trial-where safety at five ascending dose cohorts was observed-involving 15 patients who received PTB for various types o
Show less
Read more
Impact Snapshot
Event Time:
NBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIO alerts
High impacting NASCENT BIOTECH INC news events
Weekly update
A roundup of the hottest topics
NBIO
News
- Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing RunAccesswire
- Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System [Yahoo! Finance]Yahoo! Finance
- Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery SystemAccesswire
- Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates [Yahoo! Finance]Yahoo! Finance
- Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug ConjugatesAccesswire
NBIO
Sec Filings
- 4/10/24 - Form 4
- 4/10/24 - Form 4
- 4/10/24 - Form 4
- NBIO's page on the SEC website